Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | CBLB | Q13191 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421372 | 1.00 | SIRT6 (0.39) | SIRT6LTA4HALDH3A1ALDH1A3GRM2 | |
| SCHEMBL1421405 | 0.78 | LRRK2 (0.40) | SIRT6LTA4HMTOR | |
| SCHEMBL1421406 | 0.78 | LRRK2 (0.40) | SIRT6LTA4HMTOR | |
| SCHEMBL1421682 | 0.74 | CNR2 (0.40) | SIRT6LTA4HGRM2CYP2A13CBLB | |
| SCHEMBL3210795 | 0.74 | CNR2 (0.40) | SIRT6LTA4HGRM2CYP2A13CBLB | |
| SCHEMBL632786 | 0.72 | SIRT6 (0.47) | SIRT6LTA4HGRM2PIK3C3MTOR | |
| SCHEMBL632787 | 0.72 | SIRT6 (0.47) | SIRT6LTA4HGRM2PIK3C3MTOR | |
| SCHEMBL633549 | 0.71 | LTA4H (0.47) | SIRT6LTA4HGRM2MTORALDH1A1 | |
| SCHEMBL632417 | 0.71 | LTA4H (0.47) | SIRT6LTA4HGRM2MTORALDH1A1 | |
| SCHEMBL632416 | 0.71 | LTA4H (0.47) | SIRT6LTA4HGRM2MTORALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2778156-B1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | ASTRAZENECA AB (SE) | 2016-11-30 | — | — | EP | disclosed |
| EP-2778156-A1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | AstraZeneca AB (Publ) (SE) | 2014-09-17 | — | — | EP | disclosed |
| US-8273774-B2 | Phenoxypyridinylamide compounds | ASTRAZENECA AB (SE) | 2012-09-25 | — | — | US | disclosed |
| EP-2297106-A1 | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES | AstraZeneca AB (SE) | 2011-03-23 | — | — | EP | disclosed |
| US-20100041638-A1 | Chemical Compounds 293 | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| WO-2009144494-A1 | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041638-A1 | Chemical Compounds 293 | PDE4B, PDE4A, PDE3B | SIRT6 747/4885LTA4H 174/4885ALDH3A1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.